文献速递心境障碍精神分裂症与精神病性障碍

他汀类、L型钙通道拮抗剂与双胍类在严重精神障碍患者中与精神科住院及自伤率的相关性

Association of Hydroxylmethyl Glutaryl Coenzyme A Reductase Inhibitors, L-Type Calcium Channel Antagonists, and Biguanides With Rates of Psychiatric Hospitalization and Self-Harm in Individuals With Serious Mental Illness.
PubMed 文献 · JAMA Psychiatry · 2019-01-01

IMPORTANCE: Drug repurposing is potentially cost-effective, low risk, and necessary in psychiatric drug development. The availability of large, routine data sets provides the opportunity to evaluate the potential for currently used medication to benefit people with serious mental…

要点

  • 他汀类暴露与双相障碍、精神分裂症和非情感性精神病的精神科住院率降低均相关。
  • 他汀类暴露与双相障碍和精神分裂症的自伤率降低相关。
  • L型钙通道拮抗剂和双胍类暴露也与上述三类患者的精神科住院率降低相关。

核心结论

  • HMG-CoA还原酶抑制剂、L型钙通道拮抗剂和双胍类暴露可能与严重精神障碍患者精神科住院和自伤率降低相关。
  • 鉴于这些药物已知的不良事件特征,应进一步研究其作为精神症状老药新用的潜力。

研究设计与样本

  • 自身对照队列研究,比较严重精神障碍患者暴露期与非暴露期的精神科住院和自伤率,并调整多个时间变化协变量。
  • 数据分析时间为2018年4月1日至8月31日。

主要发现

  • 他汀类暴露期精神科住院率:双相障碍aHR=0.86(95%CI 0.83-0.89,P<.001),精神分裂症aHR=0.75(95%CI 0.71-0.79,P<.001),非情感性精神病aHR=0.80(95%CI 0.75-0.85,P<.001)。
  • 他汀类暴露期自伤率:双相障碍aHR=0.76(95%CI 0.66-0.86,P<.001),精神分裂症aHR=0.58(95%CI 0.45-0.74,P<.001)。
  • L型钙通道拮抗剂暴露期精神科住院率:双相障碍aHR=0.92(95%CI 0.88-0.96,P<.001),精神分裂症aHR=0.80(95%CI 0.74-0.85,P<.001),非情感性精神病aHR=0.89(95%CI 0.83-0.96,P=.002)。
  • L型钙通道拮抗剂暴露期自伤率:双相障碍aHR=0.81(95%CI 0.68-0.95,P=.01),精神分裂症aHR=0.30(95%CI 0.18-0.48,P<.001),非情感性精神病aHR=0.56(95%CI 0.42-0.74,P<.001)。
  • 双胍类暴露期精神科住院率:双相障碍aHR=0.80(95%CI 0.77-0.84,P<.001),精神分裂症aHR=0.73(95%CI 0.69-0.77,P<.001),非情感性精神病aHR=0.85(95%CI 0.79-0.92,P<.001);自伤率:双相障碍aHR=0.73(95%CI 0.62-0.84,P<.001),精神分裂症aHR=0.64(95%CI 0.48-0.85,P<.001)。

临床怎么用

  • 对于合并代谢或心血管适应症的严重精神障碍患者,处方他汀类、L型钙通道拮抗剂或双胍类时可能对精神科结局有额外获益。
  • 目前证据不支持将这些药物作为精神科适应症的常规单药治疗,需进一步前瞻性研究验证。

局限性

  • 自身对照设计无法完全排除时间变化混杂因素和适应症混杂。
  • 暴露期与非暴露期的比较可能受用药依从性和疾病严重程度波动影响。
  • 研究为观察性设计,不能确立因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Drug repurposing is potentially cost-effective, low risk, and necessary in psychiatric drug development. The availability of large, routine data sets provides the opportunity to evaluate the potential for currently used medication to benefit people with serious mental illness (SMI). OBJECTIVE: To determine whether hydroxylmethyl glutaryl coenzyme A reductase inhibitors (HMG-CoA RIs), L-type calcium channel (LTCC) antagonists, and biguanides are associated with reduced psychiatric hospitalization and self-harm in individuals with SMI. DESIGN, SETTING, AND PARTICIPANTS: These within-individual cohort studies of patients with SMI compared rates of psychiatric hospitalization and self-harm during periods of exposure and nonexposure to the study drugs, with adjusting for a number of time-varying covariates. Participants included 142 691 individuals from the entire population of Sweden with a diagnosis of bipolar disorder (BPD), schizophrenia, or nonaffective psychosis (NAP) who were 15 years or older and who were treated with psychiatric medication from October 1, 2005, through December 31, 2016. Data were analyzed from April 1 through August 31, 2018. INTERVENTIONS: Treatment with HMG-CoA RIs, LTCC antagonists, or biguanides. MAIN OUTCOMES AND MEASURES: Psychiatric hospitalizations and self-harm admissions. RESULTS: Among the 142 691 eligible participants, the HMG-CoA RI exposure periods were associated with reduced rates of psychiatric hospitalization in BPD (adjusted hazard ratio [aHR], 0.86; 95% CI, 0.83-0.89; P < .001), schizophrenia (aHR, 0.75; 95% CI, 0.71-0.79; P < .001), and NAP (aHR, 0.80; 95% CI, 0.75-0.85; P < .001) and reduced self-harm rates in BPD (aHR, 0.76; 95% CI, 0.66-0.86; P < .001) and schizophrenia (aHR, 0.58; 95% CI, 0.45-0.74; P < .001). Exposure to LTCC antagonists was associated with reduced rates of psychiatric hospitalization and self-harm in subgroups with BPD (aHRs, 0.92 [95% CI, 0.88-0.96; P < .001] and 0.81 [95% CI, 0.68-0.95; P = .01], respectively), schizophrenia (aHRs, 0.80 [95% CI, 0.74-0.85; P < .001] and 0.30 [95% CI, 0.18-0.48; P < .001], respectively), and NAP (aHRs, 0.89 [95% CI, 0.83-0.96; P = .002] and 0.56 [95% CI, 0.42-0.74; P < .001], respectively). During biguanide exposure, psychiatric hospitalization rates were reduced in subgroups with BPD (aHR, 0.80; 95% CI, 0.77-0.84; P < .001), schizophrenia (aHR, 0.73; 95% CI, 0.69-0.77; P < .001), and NAP (aHR, 0.85; 95% CI, 0.79-0.92; P < .001), and self-harm was reduced in BPD (aHR, 0.73; 95% CI, 0.62-0.84; P < .001) and schizophrenia (aHR, 0.64; 95% CI, 0.48-0.85; P < .001). CONCLUSIONS AND RELEVANCE: This study provides additional evidence that exposure to HMG-CoA RIs, LTCC antagonists, and biguanides might lead to improved outcomes for individuals with SMI. Given the well-known adverse event profiles of these agents, they should be further investigated as repurposed agents for psychiatric symptoms.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Hayes JF, Lundin A, Wicks S, et al. Association of Hydroxylmethyl Glutaryl Coenzyme A Reductase Inhibitors, L-Type Calcium Channel Antagonists, and Biguanides With Rates of Psychiatric Hospitalization and Self-Harm in Individuals With Serious Mental Illness. JAMA Psychiatry. 2019. PMID: 30624557. doi:10.1001/jamapsychiatry.2018.3907

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。